ULURU Inc. Announces the Appointment of Novartis Animal Health as the Exclusive Distributor of a Veterinary Version of Altrazeal®
ADDISON, Texas, Sept. 8 /PRNewswire/ -- ULURU Inc. (NYSE Alternext: ULU) announced today that it has signed a worldwide distribution agreement appointing Novartis the exclusive distributor of a veterinary version of Altrazeal® for marketing to the animal health sector.
Under the terms of the agreement ULURU will supply Novartis with finished product for marketing in the global markets. The agreement includes other wound care products that may be developed by ULURU that the parties mutually agree to be covered by this agreement.
Commenting on the agreement, Kerry P. Gray, President and CEO of ULURU, stated, "We are very pleased to be working with Novartis, a leading global animal health care company and one of the top 5 pharmaceutical companies in the world. Initial wound healing testing in animals with Altrazeal® produced positive results. We look forward to working with the Novartis team to establish our wound franchise as a leader in the veterinary market."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to, results of Altrazeal® in animal testing, the marketing of Altrazeal® in the veterinary market and the potential inclusion of additional products in the distribution agreement. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.
Contact: Company |
|
Kerry P. Gray |
|
(214) 905-5145 |
|
SOURCE ULURU Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article